Nkarta, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.25
- 52-Week Range
- $1.11 – $3.72
- Market Cap
- $82.37M
- P/E (TTM)
- —
- EPS (TTM)
- -1.73
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.38
- PEG Ratio
- —
- Return on Equity
- -46.58%
- Return on Assets
- -22.48%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 5.79
- Debt/Equity
- 0.33
- Total Debt
- $72.04M
- Free Cash Flow
- $-59.32M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-2.11M
Market Snapshot
About
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer treatment. The company focuses on creating allogeneic, off-the-shelf NK cell therapies using its proprietary cellular engineering platform.